Monte Rosa Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 44.48, 58.17, 17.8, 69.08, 169.09 ], "ebit_estimate": [ -204.55, -245.95, -274.83, -265.98, -218.6 ], "ebitda_estimate": [ -34, 35, null, null, null ], "net_income_estimate": [ -152.9, -182.28, -224.3, -245.43, -217.55 ], "per_share_eps_estimate": [ -1.63, -1.81, -2.29, -2.11, -2.03 ], "eps_nri_estimate": [ -1.67, -1.82, -2.26, -2.07, -1.97 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 2.07, 1, null, null, null ], "pretax_income_estimate": [ -170.53, -181.77, -224.78, -247.15, -219.53 ], "operating_cash_flow_per_share_estimate": [ 0.3, 0.67, null, null, null ], "roa_estimate": [ -3.6, 5.4, null, null, null ], "roe_estimate": [ -6.8, 11.6, null, null, null ], "gross_margin_estimate": [ 100, 96.87, 95, null, 100 ], "operating_cash_flow_estimate": [ 29.97, 66.92, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -62.61, "long_term_revenue_growth_rate_mean": "-42.58", "future_per_share_eps_estimate_growth": -63.63, "future_eps_nri_estimate_growth": -62.61, "future_revenue_estimate_growth": -42.58, "future_ebit_estimate_growth": -65.77, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -72.51, "future_pretax_income_estimate_growth": -69.27, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -1.84, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 5.52, 5.52, 5.52, 3.33, 3.33, 3.33, 3.33 ], "ebit_estimate": [ -50.68, -53.47, -56.44, -64.33, -67.5, -69.33, -72.17 ], "ebitda_estimate": [ 2, 10, 4, null, null, null, null ], "net_income_estimate": [ -35.55, -37.1, -41.02, -60.5, -64.3, -66.47, -69.2 ], "per_share_eps_estimate": [ -0.38, -0.39, -0.43, -0.59, -0.62, -0.62, -0.64 ], "eps_nri_estimate": [ -0.39, -0.4, -0.44, -0.59, -0.64, -0.64, -0.67 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -43.66, -46.92, -50.42, -60.5, -64.3, -66.47, -69.2 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -62.61, "long_term_revenue_growth_rate_mean": "-42.58", "future_per_share_eps_estimate_growth": -63.63, "future_eps_nri_estimate_growth": -62.61, "future_revenue_estimate_growth": -42.58, "future_ebit_estimate_growth": -65.77, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -72.51, "future_pretax_income_estimate_growth": -69.27, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -1.84, "future_operating_cash_flow_per_share_estimate_growth": null }